Log in

NYSEAMERICAN:IBIOIbio Stock Price, Forecast & News

-0.03 (-1.30 %)
(As of 07/9/2020 04:00 PM ET)
Today's Range
Now: $2.28
50-Day Range N/A
52-Week Range
Now: $2.28
Volume6.60 million shs
Average Volume21.07 million shs
Market Capitalization$269.86 million
P/E RatioN/A
Dividend YieldN/A
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.12 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Previous SymbolNASDAQ:IBIO



Sales & Book Value

Annual SalesN/A



Market Cap$269.86 million
Next Earnings Date8/21/2020 (Estimated)
OptionableNot Optionable

Receive IBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter.

Ibio (NYSEAMERICAN:IBIO) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Ibio?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ibio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ibio.

When is Ibio's next earnings date?

Ibio is scheduled to release its next quarterly earnings announcement on Friday, August 21st 2020. View our earnings forecast for Ibio.

When did Ibio's stock split? How did Ibio's stock split work?

Ibio's stock reverse split on Monday, June 11th 2018. The 1-10 reverse split was announced on Thursday, May 31st 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 8th 2018. An investor that had 100 shares of Ibio stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for IBIO?

1 analysts have issued 12-month price objectives for Ibio's stock. Their forecasts range from $2.55 to $2.55. On average, they anticipate Ibio's share price to reach $2.55 in the next twelve months. This suggests a possible upside of 11.8% from the stock's current price. View analysts' price targets for Ibio.

Has Ibio been receiving favorable news coverage?

News articles about IBIO stock have trended negative on Friday, according to InfoTrie. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ibio earned a daily sentiment score of -2.3 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Ibio.

Who are some of Ibio's key competitors?

What other stocks do shareholders of Ibio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ibio investors own include Inovio Pharmaceuticals (INO), Co-Diagnostics (CODX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Novavax (NVAX), Nokia Oyj (NOK), Biocept (BIOC), FuelCell Energy (FCEL) and Gilead Sciences (GILD).

Who are Ibio's key executives?

Ibio's management team includes the following people:
  • Mr. Robert B. Kay, Exec. Chairman & CEO (Age 79)
  • Mr. Robert L. Erwin, Pres (Age 66)
  • Mr. James P. Mullaney CPA, CPA, Chief Financial Officer (Age 48)
  • Mr. Terence E. Ryan, Chief Scientific Officer (Age 64)
  • Dr. Renato Lobo, Chief Medical Officer

What is Ibio's stock symbol?

Ibio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

How do I buy shares of Ibio?

Shares of IBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ibio's stock price today?

One share of IBIO stock can currently be purchased for approximately $2.28.

How big of a company is Ibio?

Ibio has a market capitalization of $269.86 million. Ibio employs 54 workers across the globe.

What is Ibio's official website?

The official website for Ibio is www.ibioinc.com.

How can I contact Ibio?

Ibio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The biotechnology company can be reached via phone at +1-302-3550650.

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.